Market Research Logo

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 03,2017: Wellness Open Living Labs, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems
Jun 28,2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Jun 01,2017: Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
Jun 01,2017: Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities
May 10,2017: Eisai: Proposed Changes in Representative Officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 6
Eisai Co Ltd - Key Facts 6
Eisai Co Ltd - Key Employees 7
Eisai Co Ltd - Key Employee Biographies 9
Eisai Co Ltd - Major Products and Services 10
Eisai Co Ltd - History 12
Eisai Co Ltd - Company Statement 19
Eisai Co Ltd - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 22
Section 2 – Company Analysis 24
Eisai Co Ltd - Business Description 24
Eisai Co Ltd - Corporate Strategy 25
Eisai Co Ltd - SWOT Analysis 26
SWOT Analysis - Overview 26
Eisai Co Ltd - Strengths 26
Eisai Co Ltd - Weaknesses 27
Eisai Co Ltd - Opportunities 28
Eisai Co Ltd - Threats 30
Eisai Co Ltd - Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios - Capital Market Ratios 32
Financial Ratios - Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios - Interim Ratios 37
Financial Ratios - Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 39
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 40
Eisai Co Ltd, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Jul 03, 2017: Wellness Open Living Labs, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems 42
Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 43
May 10, 2017: Eisai: Proposed Changes in Representative Officers 44
Apr 19, 2017: Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis 45
Mar 09, 2017: Results from Studies using PXB-Mouse being presented at ToxExpo 2017 46
Jan 18, 2017: Eisai To Participate In Access Accelerated, Global Partnership To Address Rise Of Non-Communicable Diseases 48
Jan 12, 2017: Eisai To Launch Medication Administration Support Device e-OKUSURI-SAN 49
Aug 23, 2016: EISAI To Launch Chocola BB Mouth Ulcer Repair Shot 50
Jul 11, 2016: NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care 51
Jun 30, 2016: Eisai Listed For 15th Consecutive Year In FTSE4Good Index Series, An Index For Socially Responsible Investment 52
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57
List of Tables
Eisai Co Ltd, Key Facts 6
Eisai Co Ltd, Key Employees 7
Eisai Co Ltd, Key Employee Biographies 9
Eisai Co Ltd, Major Products and Services 10
Eisai Co Ltd, History 12
Eisai Co Ltd, Subsidiaries 20
Eisai Co Ltd, Joint Venture 22
Eisai Co Ltd, Key Competitors 31
Eisai Co Ltd, Ratios based on current share price 32
Eisai Co Ltd, Annual Ratios 33
Eisai Co Ltd, Annual Ratios (Cont...1) 34
Eisai Co Ltd, Annual Ratios (Cont...2) 35
Eisai Co Ltd, Interim Ratios 37
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 39
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 40
Eisai Co Ltd, Recent Deals Summary 41
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56
List of Figuress
Eisai Co Ltd, Performance Chart (2013 - 2017)
Eisai Co Ltd, Ratio Charts
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report